Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2754362 | Clinical Lymphoma Myeloma and Leukemia | 2015 | 9 Pages |
Abstract
Early mortality (EM) is all too frequent during induction chemotherapy for acute myeloid leukemia. Older patients shoulder an undue amount of this burden as a result of the inherent biology of their disease and increased comorbidities. EM rates in academic centers have seen a sharp decline over the past 20 years; however, data from population-based registries show that EM rates for the general population have significantly lagged behind. In this review, we analyze the data available on EM in academic centers and the general population, explore recent improvements in supportive care and the use of predictive models, and finally investigate the relationship between case volume and complications during chemotherapy.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Andrew W. Hahn, Omer Jamy, Sara Nunnery, George Yaghmour, Smith Giri, Ranjan Pathak, Mike G. Martin,